S&P Futures
3,915.75 +12.00 (+0.31%) Dow Futures
31,530.00 +109.00 (+0.35%) Nasdaq Futures
12,077.25 +36.75 (+0.31%) Russell 2000 Futures
1,778.70 +8.90 (+0.50%) Crude Oil
111.08 +1.51 (+1.38%) Gold
1,827.30 +2.50 (+0.14%)
Amryt Pharma plc (AMYT)
- GlobeNewswire
Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer
Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer DUBLIN, Ireland, and Boston MA, June 27, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Dr Tracy Cunningham as Chief Medical officer (CMO) with immediate effect. Dr Cunningham joined Amryt in April 2020 as VP, Head of Development with responsibility for pre-
- GlobeNewswire
Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA
Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA Filsuvez® recently approved by the European Commission for the treatment of EB DUBLIN, Ireland, and Boston MA, June 24, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, today announces that the company plans to submit a Formal Dispute Resolution Request (FDRR) for the company’s New Drug Application (NDA
- GlobeNewswire
European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB
European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB Filsuvez® will be the first and only approved treatment for EB Patients DUBLIN, Ireland, and Boston MA, June 23, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the European Commission (EC) approval of Filsuvez® in the European Union (EU) for the treatment of parti
